INTRODUCTION
Candida albicans and emerging non-albicans Candida (NAC) species such as C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei can cause superficial infections of the oral and vaginal mucosa as well as disseminated bloodstream and deep-tissue infections. Species involvement varies by infection site and by geography. Candida infections are most often caused by C. albicans as evidenced by epidemiological studies in the United States , Europe (Klingspor et al., 2015) , and the Middle East (Sharifzadeh et al., 2013) . Of all the NAC species, C. glabrata is the most commonly isolated from patients with candidemia in North America (Sobel, 2010; Azie et al., 2012; Pfaller et al., 2014b) , and Northern Europe (Lortholary et al., 2014; Milazzo et al., 2014) , as well as other geographic areas studied with the exception of Latin America . C. glabrata is also the most common NAC species found to be the causative agent in vulvovaginal candidiasis (VVC) (Corsello et al., 2003; Holland et al., 2003; Richter et al., 2005; Vermitsky et al., 2008; Mahmoudi Rad et al., 2012) and candiduria (Sobel et al., 2000; Kauffman, 2005) . In some patient populations, for example, candidemia in patients with hematologic malignancy and VVC in diabetic patients, C. glabrata is even more common than C. albicans (Goswami et al., 2006; Ray et al., 2007; Hachem et al., 2008) . C. parapsilosis is well known for its threat to the pediatric population, as it is responsible for 17-50% of all fungemia in infants and neonates (Abi-Said et al., 1997; Krcmery et al., 1999) . C. parapsilosis is also second only to C. albicans in incidence as a cause of Candida endocarditis with mortality rates between 42 and 65% (Weems, 1992; Garzoni et al., 2007) . In the AsiaPacific region, C. tropicalis has been reported to constitute 20-45% of Candida isolates (Kothari and Sagar, 2009; . C. tropicalis infections are commonly associated with malignancy, with some studies reporting higher prevalence among patients with hematologic diseases such as acute myeloid leukemia (Weinberger et al., 2005; Nucci and Colombo, 2007; Tang et al., 2014 Tang et al., , 2015 Cornely et al., 2015) . Mortality associated with C. tropicalis candidemia in these populations unfortunately remains high, ranging from 30 to 70%, with the highest rates most commonly observed among the elderly (Weinberger et al., 2005; Nucci and Colombo, 2007; Morii et al., 2014; Cornely et al., 2015; Wang et al., 2015) . C. krusei is the fourth most common NAC species associated with invasive candidiasis and candidemia, accounting for approximately 2.7% of NAC species isolated across the United States (Pfaller et al., 2014b) . Moreover, the number of C. krusei isolates implicated in these types of infections has increased over time (Pfaller et al., 2014a,b) . In particular, patients with hematologic malignancies and bone marrow transplants have been shown to be at increased risk of C. krusei infection (Merz et al., 1986; Wingard et al., 1991; Pfaller et al., 2008) .
AZOLE RESISTANCE IN CANDIDA INFECTIONS
There are several classes of compounds that comprise the arsenal used to treat Candida infections. The polyenes, azoles, echinocandins, nucleoside analogs, and allylamines are used with varying efficacy depending on the type and site of infection and the sensitivity of the Candida species Pfaller and Diekema, 2012b; Pfaller et al., 2013; Pappas et al., 2016) . The most commonly prescribed antifungal used for most C. albicans infections is fluconazole, a member of the azole class of antifungals . Azoles inhibit 14-α-sterol demethylase, encoded by the ERG11 gene, which is an enzyme involved in the biosynthesis of the fungal-specific membrane sterol ergosterol. As some NAC species exhibit intrinsic resistance to azoles, their use is likely a contributing factor to the more frequent incidence of infections caused by these NAC species (Oxman et al., 2010; Lortholary et al., 2011; Fothergill et al., 2014) . Moreover, many studies have documented the ability of Candida to develop high-level resistance to azole antifungals (Oxman et al., 2010; Lortholary et al., 2011) . A compilation of fluconazole MIC ranges and epidemiological cutoff values for Candida species is presented in Table 1 .
Infections caused by C. albicans are associated with varying levels of fluconazole resistance depending on the type of infection. C. albicans isolates from candidemic patients have the lowest incidence of azole resistance (0-5%) Pfaller et al., 2015; Ying et al., 2015) . The incidence of fluconazole resistance in C. albicans isolates from oropharyngeal candidiasis (OPC) is higher and depends upon previous fluconazole treatment and prior OPC infections (Enwuru et al., 2008; Berberi et al., 2015) . C. glabrata has the highest incidence of azole resistance among Candida clinical isolates and exhibits intrinsic decreased susceptibility to the azole class of antifungals (Oxman et al., 2010; Pfaller et al., 2014b) , including the newest addition to the class, isavuconazole (Castanheira et al., 2014) . C. glabrata is also able to develop high-level resistance after exposure to azole antifungals (Fidel et al., 1999; Lee et al., 2009) and is one of the most frequent species isolated in breakthrough infections from patients receiving azole prophylaxis (Bennett et al., 2004; Imhof et al., 2004; Hachem et al., 2008) . Of increasing concern are the number of multidrug resistant isolates of C. glabrata that are being recovered clinically (Manzano-Gayosso et al., 2003; Chapeland-Leclerc et al., 2010; Hull et al., 2012; Pfaller et al., 2012a; Cho et al., 2015) . In the Asia-Pacific region, fluconazole resistance in C. tropicalis ranges from 0 to as high as 83% (Yang et al., 2004 (Yang et al., , 2008 Yoo et al., 2009 ). The worldwide incidence of fluconazole resistance in C. parapsilosis disseminated infections ranges between 2 and 5% (Chen et al., 2006; Martí-Carrizosa et al., 2014; Pfaller et al., 2015) . As C. krusei exhibits intrinsic resistance to fluconazole, there is some controversy whether its increased infection rate is related to fluconazole prophylaxis or previous treatment (Hope et al., 2002; Lin et al., 2005; Blot et al., 2006; Gong et al., 2016) . Clearly, an understanding of molecular mechanisms driving intrinsic and development of high-level azole resistance is warranted.
AZOLE ANTIFUNGAL RESISTANCE MECHANISMS

Candida albicans
Resistance to azole antifungals in Candida (summarized in Figure 1 ) has been most extensively studied in C. albicans. One mechanism of resistance identified in this species is the presence of point mutations in ERG11. Previous studies have identified amino acid substitutions that result in decreased fluconazole susceptibility and have noted that several of these critical allelic variations cluster in three "hot spot" regions within Erg11p (Marichal et al., 1999) . Recently, 63 fluconazole-resistant C. albicans clinical isolates were examined for mutations within their ERG11 alleles, and 55 were found to carry at least one mutation that resulted in amino acid substitutions, with nine such predicted amino acid substitutions being novel (Flowers et al., 2015) . Molecular modeling of the substitutions that resulted in decreased fluconazole susceptibility when expressed in a susceptible background revealed that the mutations clustered in either the predicted catalytic site, the fungus-specific external loop, or on the proximal surface potentially interacting with the loop or near the heme. Additionally, a study involving sitedirected mutagenesis of wild-type ERG11 to introduce mutations identified in 23 C. albicans clinical isolates demonstrated nine of these mutations result in increased fluconazole resistance (Xiang et al., 2013) . Five of the amino acid substitutions were predicted to be at or near the active site of Erg11p.
Another mechanism of fluconazole resistance in C. albicans is the increased expression of ERG11 due to activating mutations in the gene encoding the zinc-cluster transcriptional regulator Upc2p. C. albicans Upc2 is a homolog of the Saccharomyces cerevisiae ERG gene regulator pair Upc2/Ecm22. Initially, Upc2 involvement in fluconazole resistance in C. albicans was demonstrated when ∆upc2 C. albicans strains were shown to be highly susceptible to azoles while those over-expressing Upc2 had increased fluconazole resistance (MacPherson et al., 2005) . Further studies examining a matched set of fluconazolesusceptible and-resistant C. albicans clinical isolates in which fluconazole resistance was not associated with overexpression of drug efflux pumps revealed SNPs in one UPC2 allele and overexpression of several ERG genes and UPC2 in the resistant isolate (Dunkel et al., 2008a) . Expression of UPC2 alleles in fluconazole-susceptible strains resulted in increased fluconazole resistance (Dunkel et al., 2008a; Heilmann et al., 2010; Hoot et al., 2011) . Interestingly, three additional matched sets of ERG11-overexpressing clinical C. albicans isolates have been described which have no sequence differences in UPC2 between the susceptible and resistant isolates in each pair (Heilmann et al., 2010) , indicating that other mechanisms of ERG11 upregulation exist. While these studies were important in establishing Upc2p as a regulator of ERG11 expression in the context of fluconazole resistance, it was assumed that UPC2-mediated fluconazole resistance is a rare occurrence. However, a large study involving 63 fluconazole-resistant C. albicans clinical isolates demonstrated 47 of these isolates overexpressed ERG11 by at least 2-fold (Flowers et al., 2012) . Twenty-nine of these ERG11-overexpressing isolates contained a missense mutation in UPC2, and eight single amino acid substitutions were elucidated from their UPC2 alleles. Seven of these alleles were found to be associated with increased ERG11 expression, increased ergosterol production, and decreased fluconazole susceptibility.
Two other mechanisms of fluconazole resistance in C. albicans involve the overexpression of drug efflux pumps Mdr1p and Cdr1p/Cdr2p. TAC1 (transcriptional activator of CDR genes) is a zinc-cluster transcription factor whose regulon is hallmarked by the ATP-binding cassette (ABC) transporter-encoding genes CDR1 and CDR2 (Coste et al., 2004) . Activation of expression of the TAC1 regulon is through binding of TAC1 to the DRE (drug response element) present in the promoters of TAC1-regulated genes (Coste et al., 2004; Liu et al., 2007) . At least nine hyperactive TAC1 alleles have been identified (Coste et al., 2007) , and fluconazole minimum inhibitory concentrations (MIC) associated with the isolates from which these alleles have been discovered have revealed that TAC1 demonstrates codominance resulting in intermediate fluconazole MIC in TAC1-heterologous strains and high fluconazole MIC upon loss of heterozygosity (Coste et al., 2006 (Coste et al., , 2007 . Because TAC1 resides on the left arm of Chr5 with ERG11, such loss of heterozygosity in the presence of hyperactive TAC1 and mutated ERG11 results in high-level azole resistance (Coste et al., 2007; Selmecki et al., 2008) .
Mdr1p is a major facilitator superfamily (MFS) efflux pump usually expressed at non-detectable levels in wildtype C. albicans strains, induced in the presence of benomyl, diamide, and hydrogen peroxide, and constitutively overexpressed in some fluconazole-resistant C. albicans isolates (Alarco and Raymond, 1999) . MRR1, multidrug resistance regulator 1, was identified by comparing the transcriptomes of sets of matched isolates in which the fluconazole-resistant isolates overexpressed MDR1 (Morschhäuser et al., 2007) . Disruption of MRR1 in these resistant isolates led to a decrease in fluconazole MIC, while introduction of each of the mutant alleles individually into a wildtype fluconazole-susceptible background in the native MRR1 locus conferred fluconazole resistance to the constructed strain. Another study examined additional MRR1 allelic variations in MDR1-mediated fluconazole resistance (Dunkel et al., 2008b) . In most cases the resistant isolates/strains were homozygous for the MRR1 allele containing the gain-of-function mutations due to mitotic recombination and chromosome loss.
A less common mechanism of azole resistance in C. albicans is inactivation of the ERG3 gene, which encodes the ergosterol biosynthesis enzyme sterol 5, 6 desaturase. Erg3p catalyzes one of the final steps in the pathway and also converts nontoxic 14α-methylated sterol intermediates, that accumulate during azole treatment, into the toxic sterol 14α-methylergosta-8,24(28)-dien-3β,6α-diol. Inactivation or deletion of the ERG3 gene, therefore, prevents such toxic sterols from being synthesized. Only a handful of clinical C. albicans isolates have documented azole resistance due to ERG3 inactivation Nolte et al., 1997; Miyazaki et al., 1999; Chau et al., 2005; Martel et al., 2010; Morio et al., 2012) .
Aneuploidy plays a role in azole resistance in C. albicans as demonstrated by comparative genome hybridization . As alluded to earlier, a common aneuploidy found in azole-resistant strains involves Chr5. Similarly, loss of heterozygosity (LOH) has been shown to occur in azoleresistant C. albicans (Coste et al., 2006) . Examination of TAC1 in a matched set of azole-susceptible and-resistant C. albicans isolates revealed that the susceptible isolate harbored two wildtype alleles of TAC1, while the resistant isolate contained only one of those alleles in which a single nucleotide polymorphism (SNP) translated into an activating amino acid substitution (N977D).
Candida parapsilosis
Because azole resistance has been extensively studied in C. albicans, attempts to elucidate mechanisms of azole resistance in C. parapsilosis have involved examining orthologous genes and yielded mixed results. A study of a series of six isolates from a single patient found a single SNP in MRR1 present in the two fluconazole-resistant isolates . Nine fluconazole-resistant isolates were obtained from candidemia patients in a Brazilian hospital and examined for CDR1, MDR1, and ERG11 overexpression as well as the presence of SNPs in the ERG11 gene (Souza et al., 2015) . Each of the resistant isolates possessed a single homozygous SNP (A395T) which corresponds to a Y132F amino acid substitution. In addition, while none of the isolates overexpressed MDR1 as compared to the C. parapsilosis reference strain ATCC22019, CDR1 expression was between 3.3-and 9.2-fold higher in these isolates as compared to the reference strain, and ERG11 was overexpressed between 1.5-and 7.4-fold. While this study indicated an association between CDR1 and ERG11 and fluconazole resistance in C. parapsilosis, a causal link was not definitively proven.
In a larger-scale study, 30 resistant isolates, 37 susceptibledose-dependent isolates, and 55 susceptible isolates were collected from hospitals in four U.S. cities, and their ERG11 genes were sequenced (Grossman et al., 2015) . Five SNPs were identified in 54 of the isolates; amino acid substitution Y132F, found in 17 resistant isolates, was the only one found exclusively in resistant isolates. Twenty-three isolates harbored SNPs in MRR1. Of the nine SNPs identified, only three were found exclusively in resistant isolates. Quantitative PCR measuring relative MDR1 expression revealed nine isolates (six with a SNP in MRR1, three without) with at least 5-fold increase in MDR1 expression compared to a composite expression level from a subset of susceptible isolates. However, the expression levels were a fraction of the levels achieved by MDR1-mediated azole resistance in C. albicans. Without definitive experiments in which introduction of a mutated ERG11 allele confers azole resistance in a susceptible isolate, these results remain suggestive.
In an effort to identify potential mechanisms of azole resistance on a genome-wide scale in C. parapsilosis, fluconazole-, voriconazole-, and posaconazole-resistant strains were developed experimentally by serial passage in liquid culture containing either fluconazole, voriconazole, or posaconazole (Silva et al., 2011) . The fluconazole-and voriconazole-resistant strains were cross-resistant to both fluconazole and voriconazole and possessed similar transcriptional profiles as assessed by microarray analysis; however, the posaconazole-resistant strain was not cross-resistant to the other azoles and had a distinct transcriptional profile. Among the genes differentially expressed in fluconazole-and voriconazole-resistant strains were the stress response gene GRP2, as well as MDR1 and MRR1. ERG11 was not differentially expressed in these strains. However, in the posaconazole-resistant strain, the ergosterol biosynthesis genes ERG11 and ERG6, as well as ERG gene regulator UPC2 were among the genes differentially expressed.
In a study using laboratory strains of C. parapsilosis in which previously-determined gain-of-function alleles of CpMRR1 were introduced into the native locus, strains containing Mrr1p with a G583R amino acid substitution from a fluconazoleresistant C. parapsilosis isolate led to resistant fluconazole and voriconazole MIC compared to strains harboring the wildtype allele (Branco et al., 2015) . Similarly, strains with single SNPcontaining MRR1 alleles had a ∼5-fold increase in MRR1 gene expression and ∼70-fold increase in MDR1 gene expression.
In another study, 35 unrelated fluconazole-resistant and four unrelated susceptible isolates of C. parapsilosis were examined to elucidate mechanisms of fluconazole resistance in C. parapsilosis (Berkow et al., 2015) . Sixteen resistant isolates overexpressed CDR1, three other resistant isolates exhibited MDR1 overexpression, and eight resistant isolates demonstrated overexpression of ERG11 as compared to the susceptible isolates. When sequencing orthologues of UPC2, MRR1, and TAC1 in order to identify putative gain-of-function mutations that would lead to overexpression of ERG11, MDR1, and CDR1, only one heterozygous mutation in UPC2 was recovered from one isolate, suggesting that ERG11 overexpression in fluconazole-resistant C. parapsilosis is not mediated by UPC2. TAC1 mutations that were recovered did not fully correspond with CDR1 overexpression and those recovered were not analogous to those found in gain-of-function CaTAC1 alleles. Similarly, MRR1 mutations recovered did not correspond to any mutations found in gainof-function alleles of CaMRR1. Subsequently, CDR1 was deleted from three of the CDR1-overexpressing isolates which only resulted in a one-dilution decrease in fluconazole MIC. MDR1 deletion in three MDR1-overexpressing isolates revealed a onedilution decrease in fluconazole MIC in two isolates and no change in fluconazole MIC in the third. To address the role of alterations in the ergosterol biosynthesis pathway in azole resistance in C. parapsilosis, ERG11, and ERG3 were sequenced. No ERG3 mutations were recovered, which was supported by the sterol profiles of the isolates. A single ERG11 mutation (Y132F) was recovered in one resistant isolate and a combination of Y132F and R398I mutations was found in an additional ten isolates. In nine of these eleven isolates there was a change in the sterol profile indicative of a change in Erg11 functionality. This study indicates that while differential expression of efflux pumps is commonly found in azole-resistant C. parapsilosis isolates, the resistant phenotype is not solely due to their overexpression but instead is multifactorial and involves ERG11 mutation and/or overexpression.
Candida tropicalis
As compared with other species of Candida, relatively little is known about the mechanisms of azole resistance in C. tropicalis. An analysis of 52 clinical C. tropicalis isolates from China found the average ERG11 expression level more than 4-fold higher among fluconazole-resistant isolates than -susceptible isolates (Jiang et al., 2013) . Moreover, ERG11 expression was even higher among a subset of fluconazole-resistant isolates also resistant to itraconazole and voriconazole. These results were recently echoed by a similar study characterizing 35 C. tropicalis isolates from Korean university hospitals, nine of which were fluconazole-non-susceptible (Choi et al., 2016) . While considerable variability in ERG11 expression (∼150-fold) was observed in the highly fluconazole-susceptible group, ERG11 expression was significantly higher among both less fluconazolesusceptible (MIC 1-2 µg/ml) and fluconazole-non-susceptible (MIC ≥ 4 µg/ml) isolates. This study also sequenced the C. tropicalis UPC2 gene and found several heterozygous and homozygous mutations. However, many of these mutations have been observed in fluconazole-susceptible isolates not found to overexpress ERG11, and further characterization of their impact on the regulatory function of UPC2 is needed.
Molecular characterization of azole-resistant clinical C. tropicalis isolates has also revealed alterations in the ergosterol biosynthetic pathway (Vandeputte et al., 2005; Eddouzi et al., 2013; Jiang et al., 2013; Choi et al., 2016) . A fluconazole-resistant C. tropicalis isolate recovered from a clinical blood specimen from Tunisia was found to have mutations in both ERG3 and ERG11 which were individually observed to be detrimental to ergosterol biosynthesis when heterologously expressed in S. cerevisiae (Eddouzi et al., 2013) . Notably, the ERG11 mutation in this isolate consisted of a deletion of 132 nucleotides resulting in a D275V amino acid substitution and the loss of 44 amino acids near the N-terminus of Erg11p. Homozygous replacement of the wild-type C. tropicalis ERG11 with the truncated clinical variant, with or without the associated clinical ERG3 mutation, resulted in high-level fluconazole resistance in a fluconazole-susceptible reference strain of C. tropicalis. Additionally, an ERG11 mutation resulting in decreased fluconazole susceptibility due to the amino acid substitution Y132F, has been well characterized in C. albicans and was recently observed in a fluconazole-resistant C. tropicalis isolate from a patient with candidemia (Tan et al., 2015) .
One of the first studies to associate the overexpression of efflux pumps with azole resistance in C. tropicalis utilized serial passaging of a reference C. tropicalis isolate on media containing various concentrations of fluconazole to produce geneticallyrelated isolates with reduced fluconazole susceptibility (Barchiesi et al., 2000) . After passaging, all isolates with reduced susceptibility to fluconazole demonstrated increased expression of both C. tropicalis MDR1 and a gene with high homology to C. albicans CDR1. In both cases, the increased expression was found to then be diminished in fluconazole-susceptible revertants obtained from further passaging on fluconazolefree media. The role of efflux pump overexpression in azole resistance among clinical C. tropicalis isolates has been less clearly defined. When the expression of MDR1 and CDR1 was examined in the aforementioned 52 clinical C. tropicalis isolates from China, no significant difference was observed between fluconazole-susceptible and -resistant isolates (Jiang et al., 2013) . In contrast, among the 35 clinical isolates from Korean university hospitals, expression of both MDR1 and CDR1 was observed to be significantly higher among both less-fluconazole-susceptible and fluconazole-non-susceptible isolates. However, it is important to note the large degree of variability in the expression of MDR1 and CDR1 observed in the highly fluconazole-susceptible control group, ∼50-fold and ∼30-fold respectively . To date, experiments to directly delineate the potential role of these efflux pumps has yet to be performed in C. tropicalis, and the homologs of C. albicans MRR1 and TAC1 have not been examined.
Candida krusei
C. krusei is intrinsically resistant to fluconazole, though the precise mechanism is not completely understood. Several studies have attributed C. krusei's innate azole resistance to efflux pump activity, namely through the ATP-binding cassette transporter Abc1p, and reduced drug accumulation (Marichal et al., 1995; Katiyar and Edlind, 2001; Lamping et al., 2009) in combination with reduced azole affinity for Erg11p (Marichal et al., 1995; Venkateswarlu et al., 1997; Orozco et al., 1998; Guinea et al., 2006; Lamping et al., 2009) . Changes in the cell membrane affecting membrane fluidity may be implicated in azole resistance as well since there is evidence to suggest that intracellular azole accumulation occurs through one or possibly both mechanisms of passive and facilitated diffusion (Mansfield et al., 2010; Kolaczkowska and Kolaczkowski, 2016) . Additionally, the discovery of a trisomy in the ERG11-containing chromosome in a C. krusei strain suggests aneuploidy may not be uncommon in this species, though the effects as it relates to azole resistance are not yet known (Lamping et al., 2009) .
Resistance mechanisms against other azoles are also not clearly defined. For example, analysis of itraconazole-resistant C. krusei isolates revealed that reduced intracellular content of the drug and not altered affinity for the drug target likely drives itraconazole resistance (Marichal et al., 1995; Venkateswarlu et al., 1996) . However, more recently it has been suggested that overexpression of genes encoding both Erg11p and the efflux pump Abc2p may also play a role with itraconazole resistance (Tavakoli et al., 2010; He et al., 2015) . Despite its fungicidal activity in C. krusei (Rubio et al., 2005) , resistance to voriconazole has also emerged, and current research supports a theory where overexpression of the genes encoding the efflux pump Abc2 and Erg11 impart more transient resistance properties, while increased expression of Abc1p and point mutations in ERG11 predominate as time progresses to yield a stably resistant pathogen in the prolonged presence of voriconazole (Ricardo et al., 2014) . Erg11p amino acid substitutions have been observed in azole-resistant C. krusei and, in the case of Y166S, have been predicted to interfere with Erg11p function (Ricardo et al., 2014; Silva et al., 2016) . While the newer antifungal agents posaconazole and isavuconazole have shown good activity against C. krusei ( Lee et al., 2000; Rybak et al., 2015) , reports of resistance against these agents are relatively sparse (Espinel-Ingroff et al., 2014; Pfaller et al., 2015) . However, in a recent analysis examining NAC strains in the U.S. by region, Candida krusei resistance to posaconazole was highest in the eastern United States, with posaconazole resistance occurring in 13-16.7% of isolates (Pfaller et al., 2014b) . Nevertheless, the mechanisms of resistance in C. krusei against these agents remain to be investigated.
Candida glabrata
C. glabrata is unique among the Candida species discussed here as it is a haploid yeast more closely related to S. cerevisiae. Development of azole resistance in clinical isolates of C. glabrata has been almost exclusively linked to the presence of activating mutations in the zinc cluster transcription factor Pdr1 (Vermitsky and Edlind, 2004 ) that lead to differential expression of downstream targets. Nearly all clinical isolates have been found to have PDR1 mutations, with such mutations found in the inhibitory domain, activating domain, middle homology region, and xenobiotic binding region. The rapid acquisition of PDR1 mutations could be due to the high incidence of mutations in the mismatch repair gene MSH2, which results in a hypermutable phenotype (Healey et al., 2016) . The activating mutations exhibit distinct expression patterns of the downstream effector genes, with the exception of increased expression of CDR1 and PUP1, and no correlation has been found between location of the mutation and altered gene expression (Tsai et al., 2006 (Tsai et al., , 2010 Ferrari et al., 2009; Caudle et al., 2011; Paul et al., 2011) . Among the genes whose pleiotropic drug response element (PDRE) is directly bound by Pdr1 (Paul et al., 2014) , only three, the ABC transporters CDR1 (Sanglard et al., 1999) , PDH1 (CDR2) (Miyazaki et al., 1998; Sanglard et al., 2001) , and SNQ2 (Sanguinetti et al., 2005; Torelli et al., 2008) , have been linked directly to azole resistance. Recent work has shown increased expression of four MFS transporters in clotrimazole resistant isolates compared to clotrimazole susceptible clinical isolates. Disruption of one of these, TPO3, moderately increased susceptibility to clotrimazole and fluconazole (Costa et al., 2016) . These findings suggest MFS transporters may have a minor role in azole resistance in C. glabrata.
Surprisingly, ERG11 does not appear to play an important role in clinical azole resistance in C. glabrata (Sanglard et al., 1999; Vermitsky and Edlind, 2004; Sanguinetti et al., 2005) . Increased expression of ERG11 has been observed in only two clinical isolates of C. glabrata (vanden Bossche et al., 1992; Redding et al., 2003) . The upregulation in one isolate was later found to be due to duplication of the entire chromosome containing ERG11 and the phenotype was lost with subsequent passaging in azole-free media (Marichal et al., 1997) . A single resistant clinical isolate of C. glabrata has been shown to have a nonfunctional 14-α-sterol demethylase due to a missense mutation in ERG11, which led to the complete absence of ergosterol in the cell membrane (Hull et al., 2012) . No additional clinical isolates have been identified to have resistance mechanisms related to the azole target.
C. glabrata has the ability to grow with altered cell membrane sterols, which allows for evasion of azole treatment. C. glabrata is able to take up exogenous sterols (Nakayama et al., 2000) , both when the ergosterol biosynthesis pathway is blocked and under normal conditions in wild type strains (Tsai et al., 2004; Bard et al., 2005) . Aus1p has been identified as the sterol transporter responsible for tolerance to azoles in the presence of exogenous sterols (Nakayama et al., 2007) . C. albicans has recently been shown to take up sterols under aerobic conditions; however, C. glabrata is more liberal in its ability to take up sterols and does so in both aerobic and anaerobic conditions and, in the presence of serum and fluconazole, enhances uptake under aerobic conditions (Zavrel et al., 2013) .
Azole resistance in C. glabrata has also been attributed to the formation of petite mutants, which are cells that have lost mitochondrial function resulting in respiratory deficiency (Defontaine et al., 1999; Brun et al., 2003) . Petite mutants can be generated in the laboratory by treatment with azoles or ethidium bromide. This mutant phenotype has been recovered clinically (Bouchara et al., 2000; Ferrari et al., 2011) , but is not common among clinical isolates. Azole resistance in petite mutants has been attributed to upregulation of the ABC transporters CDR1, CDR2, and SNQ2 (Sanglard et al., 2001; Ferrari et al., 2011) , which is dependent on Pdr1 (Tsai et al., 2006) . Petite mutants exhibit altered sterol profiles with a disproportionate amount of ergosterol and very little of ergosterol intermediates; however, no changes in the sequence of ERG11 or its expression have been detected (Brun et al., 2004) .
CONCLUSIONS
Candida species are responsible for a majority of superficial and disseminated fungal infections in humans. While azole antifungals have long provided effective treatment for such infections, recent epidemiological studies indicate that intrinsic azole resistance in some Candida species as well as development of high-level azole resistance is a problem of critical importance in the clinical setting. While extensive studies to elucidate molecular mechanisms of high-level azole resistance in C.
albicans has uncovered the role of ergosterol biosynthesis gene mutation and ERG gene and drug efflux pump upregulation as key mediators of azole resistance, there are clearly other factors at play that contribute significantly to such resistance. Similarly, while NAC are closely related to C. albicans, that does not necessarily translate to analogous molecular mechanisms of azole resistance.
Of the NAC species highlighted in this review, C. parapsilosis, C. tropicalis, C. krusei, and C. glabrata all express ABC transporter and/or MFS genes orthologous to CaCDR1 and CaMDR1. However, as discussed, the altered expression of these genes in azole-resistant NAC appear to contribute differently to resistance in different species. Moreover, the transcriptional regulators and genetic mutations governing azole efflux and sterol biosynthesis in C. tropicalis, C. parapsilosis, and C. krusei have not been fully examined. Finally, there exist clear differences in the mutations in ERG11 that are found to influence azole resistance in clinical isolates among these species. As azole resistance continues to emerge in these species, a more complete understanding of the important differences among resistance mechanisms employed by these species will be needed in order to circumvent this important clinical problem.
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